EXOZ insider filings
EXOZYMES INC. — 23 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-26. Screen EXOZ transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 12 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 5 legs across 1 filing by 1 insider — 855 shares, $6,405 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing by 1 insider — 3,729 shares, $19,427 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: sale of 3,729 shares @ $5.21 ($19,427) by Perriman Damien Alan, filed 2026-10-26.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Perriman Damien Alan — Chief Commercial Officer | 2 | — | 1 leg · 3,729 sh · $19,427 | 4 |
| Heltzen Michael — Chief Executive Officer | 1 | 5 legs · 855 sh · $6,405 | — | 1 |
| Korman Tyler Paz — Chief Scientific Officer | 2 | — | — | 2 |
| BELL LON E — Director | 1 | — | — | 1 |
| Bowie James Ulrich — Director | 1 | — | — | 1 |
| DIGIANDOMENICO ANTHONY — Director, 10% owner | 1 | — | — | 1 |
| Lalonde James Joseph — Director | 1 | — | — | 1 |
| MARLETT CHRISTOPHER A — Director, 10% owner | 1 | — | — | 1 |
| Nawaz Fouad — Vice President- Finance | 1 | — | — | 1 |
| Rayo Edgardo Javier — Director | 1 | — | — | 1 |
Recent insider filings — EXOZYMES INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-26 | 4 | Perriman Damien Alan — Chief Commercial Officer | Option exercise (M): 3,922 · Sale (S): 3,729 @ $5.21 · Option exercise (M): 3,922 (derivative) @ $0 | EDGAR |
| 2026-10-21 | 4/A | Korman Tyler Paz — Chief Scientific Officer | Holdings only — no transactions reported | EDGAR |
| 2026-10-19 | 4 | MARLETT CHRISTOPHER A — Director, 10% owner | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-10-19 | 4 | Rayo Edgardo Javier — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-10-19 | 4 | BELL LON E — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-10-19 | 4 | Bowie James Ulrich — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-10-19 | 4 | DIGIANDOMENICO ANTHONY — Director, 10% owner | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-10-19 | 4 | Lalonde James Joseph — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-09-17 | 4 | Nawaz Fouad — Vice President- Finance | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2026-09-02 | 4 | Heltzen Michael — Chief Executive Officer | Purchase (P): 4 @ $7.58 · Purchase (P): 251 @ $7.35 · Purchase (P): 250 @ $7.60 · Purchase (P): 250 @ $7.52 · Purchase (P): 100 @ $7.50 · Grant/award (A): 8,841 @ $6.40 | EDGAR |
| 2026-08-25 | 4 | Perriman Damien Alan — Chief Commercial Officer | Option exercise (M): 19,612 · Option exercise (M): 19,612 (derivative) @ $0 | EDGAR |
| 2026-08-25 | 4 | Korman Tyler Paz — Chief Scientific Officer | Option exercise (M): 32,964 · Option exercise (M): 32,964 (derivative) @ $0 | EDGAR |
| 2026-04-10 | 4 | Korman Tyler Paz — Chief Scientific Officer | Sale (S): 750 @ $10.04 · Sale (S): 750 @ $10.53 | EDGAR |
| 2026-04-08 | 4 | Perriman Damien Alan — Chief Commercial Officer | Grant/award (A): 62,759 @ $0 · Grant/award (A): 146,437 (derivative) @ $0 | EDGAR |
| 2026-04-08 | 4 | Perriman Damien Alan — Chief Commercial Officer | Grant/award (A): 8,887 @ $8.44 | EDGAR |
| 2026-04-08 | 4 | Opgenorth Paul Hideo — Vice President, Development | Grant/award (A): 3,999 @ $8.44 | EDGAR |
| 2026-04-08 | 4 | Nawaz Fouad — Vice President- Finance | Grant/award (A): 5,999 @ $8.44 | EDGAR |
| 2026-04-08 | 4 | Korman Tyler Paz — Chief Scientific Officer | Grant/award (A): 5,332 @ $8.44 | EDGAR |
| 2025-07-02 | 4 | Heltzen Michael — Chief Executive Officer | Purchase (P): 1,040 @ $10.22 | EDGAR |
| 2025-06-20 | 4 | Heltzen Michael — Chief Executive Officer | Grant/award (A): 235,817 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | Korman Tyler Paz — Vice President, Research | Grant/award (A): 2,990 @ $12.54 | EDGAR |
| 2025-06-17 | 4 | Opgenorth Paul Hideo — Vice President, Development | Grant/award (A): 2,990 @ $12.54 | EDGAR |
| 2025-06-17 | 4 | Nawaz Fouad — Vice President, Finance | Grant/award (A): 3,489 @ $12.54 | EDGAR |
Recent 8-K events — EXOZYMES INC.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-19 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-10-09 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-18 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-26 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-10 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-31 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Registration filings — EXOZYMES INC.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-299905 (S-1) — latest: Initial registration (S-1), filed 2026-11-06
GET https://api.filingpulse.io/v1/insider-trades?ticker=EXOZ returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs